SIGNATOPE
Reutlingen
About SIGNATOPE
It develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays. SIGNATONE immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE´s immunoassays.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $671.0K
- Funding stage: Seed
- Last round: Seed (May 2017)
- Website: signatope.com
- Phone: +4971217440862
Industries & Categories
Biotechnology, Clinical Trials, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/signatope-170070 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.